A Quick Look at Today's Ratings for Artivion(AORT.US), With a Forecast Between $32 to $35
Artivion Is Maintained at Outperform by Oppenheimer
Artivion Analyst Ratings
Artivion (AORT) Gets a Buy From Oppenheimer
Needham Maintains Artivion(AORT.US) With Buy Rating, Raises Target Price to $34
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Artivion (AORT) and RxSight (RXST)
JMP Securities Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $33
Artivion's Strong Financial Performance and Strategic Growth Opportunities Drive Buy Rating
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $32
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $32
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $32
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $32
Artivion Initiated at Market Outperform by JMP Securities
Artivion Analyst Ratings
JMP Securities Initiates Artivion(AORT.US) With Buy Rating, Announces Target Price $33
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $32
Needham Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $30
Buy Rating for Artivion's Stock on Promising AMDS Outlook and Financial Impact
Needham Reiterates Buy on Artivion, Maintains $30 Price Target
Artivion Is Maintained at Buy by Stifel